{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:13:38Z","timestamp":1790993618540,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s12325-024-02875-0","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T18:02:23Z","timestamp":1716832943000},"page":"2890-2906","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Epidemiology and Treatment Patterns of Patients with Vitiligo: A Real-World Analysis"],"prefix":"10.1007","volume":"41","author":[{"given":"Yuval","family":"Ramot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vered","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Harbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,27]]},"reference":[{"key":"2875_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1600-0749.2007.00384.x","volume":"20","author":"RA Spritz","year":"2007","unstructured":"Spritz RA. The genetics of generalized vitiligo and associated autoimmune diseases. Pigment Cell Res. 2007;20:271\u20138.","journal-title":"Pigment Cell Res"},{"key":"2875_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1600-0625.2007.00666_1.x","volume":"17","author":"L Ralf Paus","year":"2008","unstructured":"Ralf Paus L, Schallreuter K, Bahadoran P, et al. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol. 2008;17:139\u201340.","journal-title":"Exp Dermatol"},{"key":"2875_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2016.10.048","volume":"77","author":"M Rodrigues","year":"2017","unstructured":"Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE, Vitiligo Working Group. New discoveries in the pathogenesis and classification of vitiligo. J Am Acad Dermatol. 2017;77:1\u201313.","journal-title":"J Am Acad Dermatol"},{"key":"2875_CR4","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/jdv.12171","volume":"28","author":"R Speeckaert","year":"2014","unstructured":"Speeckaert R, van Geel N. Distribution patterns in generalized vitiligo. J Eur Acad Dermatol Venereol. 2014;28:755\u201362.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2875_CR5","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/pcmr.12878","volume":"33","author":"ZA Abdel-Malek","year":"2020","unstructured":"Abdel-Malek ZA, Jordan C, Ho T, Upadhyay PR, Fleischer A, Hamzavi I. The enigma and challenges of vitiligo pathophysiology and treatment. Pigment Cell Melanoma Res. 2020;33:778\u201387.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"9988","key":"2875_CR6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","volume":"386","author":"KEV Ezzedine","year":"2015","unstructured":"Ezzedine KEV, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(14)60763-7.","journal-title":"Lancet"},{"key":"2875_CR7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jaad.2015.08.063","volume":"74","author":"L Gill","year":"2016","unstructured":"Gill L, Zarbo A, Isedeh P, Jacobsen G, Lim HW, Hamzavi I. Comorbid autoimmune diseases in patients with vitiligo: a cross-sectional study. J Am Acad Dermatol. 2016;74:295\u2013302.","journal-title":"J Am Acad Dermatol"},{"key":"2875_CR8","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/jdv.12169","volume":"28","author":"N van Geel","year":"2014","unstructured":"van Geel N, Speeckaert M, Brochez L, Lambert J, Speeckaert R. Clinical profile of generalized vitiligo patients with associated autoimmune\/autoinflammatory diseases. J Eur Acad Dermatol Venereol. 2014;28:741\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2875_CR9","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jaad.2019.07.036","volume":"82","author":"A Hadi","year":"2020","unstructured":"Hadi A, Wang JF, Uppal P, Penn LA, Elbuluk N. Comorbid diseases of vitiligo: a 10-year cross-sectional retrospective study of an urban US population. J Am Acad Dermatol. 2020;82:628\u201333.","journal-title":"J Am Acad Dermatol"},{"key":"2875_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7525-1-58","volume":"1","author":"D Parsad","year":"2003","unstructured":"Parsad D, Dogra S, Kanwar AJ. Quality of life in patients with vitiligo. Health Qual Life Outcomes. 2003;1:1\u20133.","journal-title":"Health Qual Life Outcomes"},{"key":"2875_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/pde.12226","volume":"31","author":"JI Silverberg","year":"2014","unstructured":"Silverberg JI, Silverberg NB. Quality of life impairment in children and adolescents with vitiligo. Pediatr Dermatol. 2014;31:309\u201318.","journal-title":"Pediatr Dermatol"},{"key":"2875_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13418","volume":"33","author":"RE Simons","year":"2020","unstructured":"Simons RE, Zevy DL, Jafferany M. Psychodermatology of vitiligo: psychological impact and consequences. Dermatol Ther. 2020;33:e13418.","journal-title":"Dermatol Ther"},{"key":"2875_CR13","doi-asserted-by":"crossref","unstructured":"Mayo MJ, Carey E, Smith HT, et al. Impact of pruritus on quality of life and current treatment patterns in patients with primary biliary cholangitis. Dig Dis Sci. 2023;68(3):995\u20131005.","DOI":"10.1007\/s10620-023-08050-9"},{"key":"2875_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1365-2133.2012.11197.x","volume":"168","author":"A Taieb","year":"2013","unstructured":"Taieb A, Alomar A, B\u00f6hm M, et al. Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2013;168:5\u201319.","journal-title":"Br J Dermatol"},{"key":"2875_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13215","volume":"33","author":"K Agarwal","year":"2020","unstructured":"Agarwal K, Podder I, Kassir M, et al. Therapeutic options in vitiligo with special emphasis on immunomodulators: a comprehensive update with review of literature. Dermatol Ther. 2020;33:e13215.","journal-title":"Dermatol Ther"},{"key":"2875_CR16","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1136\/flgastro-2015-100618","volume":"7","author":"VS Hegade","year":"2016","unstructured":"Hegade VS, Bolier R, Oude Elferink RP, Beuers U, Kendrick S, Jones DE. A systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis. Frontline Gastroenterol. 2016;7:158\u201366.","journal-title":"Frontline Gastroenterol"},{"key":"2875_CR17","first-page":"362A","volume":"60","author":"VS Hegade","year":"2014","unstructured":"Hegade VS, Mells G, Beuers U, et al. Patient experience and characteristics of cholestatic pruritus in the UK-PBC research cohort. Hepatology. 2014;60:362A-A363.","journal-title":"Hepatology"},{"key":"2875_CR18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"2875_CR19","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s12325-017-0582-z","volume":"34","author":"S Shrestha","year":"2017","unstructured":"Shrestha S, Miao R, Wang L, Chao J, Yuce H, Wei W. Burden of atopic dermatitis in the United States: analysis of healthcare claims data in the Commercial, Medicare, and Medi-Cal databases. Adv Ther. 2017;34:1989\u20132006.","journal-title":"Adv Ther"},{"key":"2875_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.613031","volume":"12","author":"Q Yang","year":"2021","unstructured":"Yang Q, Zhang G, Su M, et al. Vitiligo skin biomarkers associated with favorable therapeutic response. Front Immunol. 2021;12:613031.","journal-title":"Front Immunol"},{"key":"2875_CR21","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1159\/000354607","volume":"227","author":"VM Sheth","year":"2014","unstructured":"Sheth VM, Guo Y, Qureshi AA. Comorbidities associated with vitiligo: a ten-year retrospective study. Dermatology. 2014;227:311\u20135.","journal-title":"Dermatology"},{"issue":"11","key":"2875_CR22","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1111\/jdv.19447","volume":"37","author":"K Ezzedine","year":"2023","unstructured":"Ezzedine K, Seneschal J, Da Silva A, et al. Vitiligo patient population and disease burden in France: VIOLIN study results from the CONSTANCES cohort. J Eur Acad Dermatol Venereol. 2023;37(11):2249\u201358.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"2875_CR23","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1016\/j.jid.2023.04.013","volume":"143","author":"J Ferguson","year":"2023","unstructured":"Ferguson J, Eleftheriadou V, Nesnas J. Risk of melanoma and non-melanoma skin cancer in people with vitiligo: UK population-based cohort study. J Investig Dermatol. 2023;143(11):2204\u201310.","journal-title":"J Investig Dermatol"},{"key":"2875_CR24","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/bjd.12111","volume":"168","author":"H Teulings","year":"2013","unstructured":"Teulings H, Overkamp M, Ceylan E, et al. Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners. Br J Dermatol. 2013;168:162\u201371.","journal-title":"Br J Dermatol"},{"key":"2875_CR25","doi-asserted-by":"publisher","first-page":"5617838","DOI":"10.1155\/2017\/5617838","volume":"2017","author":"V Vachiramon","year":"2017","unstructured":"Vachiramon V, Onprasert W, Harnchoowong S, Chanprapaph K. Prevalence and clinical characteristics of itch in vitiligo and its clinical significance. BioMed Res Int. 2017;2017:5617838.","journal-title":"BioMed Res Int"},{"key":"2875_CR26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/bjd.21087","volume":"187","author":"V Eleftheriadou","year":"2022","unstructured":"Eleftheriadou V, Thompson A, Nesnas J. Vitiligo diagnosis is associated with an increase in new-onset depression and anxiety: a population-based cohort study in the UK. Br J Dermatol. 2022;187:10.","journal-title":"Br J Dermatol"},{"key":"2875_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.33880\/ejfm.2020090105","volume":"9","author":"A \u00d6ztekin","year":"2020","unstructured":"\u00d6ztekin A, \u00d6ztekin C. Sleep quality and depression in vitiligo patients. Eurasian J Family Med. 2020;9:35\u201341.","journal-title":"Eurasian J Family Med"},{"key":"2875_CR28","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/j.1365-2133.2005.06456.x","volume":"152","author":"K Ongenae","year":"2005","unstructured":"Ongenae K, Van Geel N, De Schepper S, Naeyaert J-M. Effect of vitiligo on self-reported health-related quality of life. Br J Dermatol. 2005;152:1165\u201372.","journal-title":"Br J Dermatol"},{"key":"2875_CR29","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1365-2133.2010.09828.x","volume":"163","author":"A Thompson","year":"2010","unstructured":"Thompson A, Clarke S, Newell RJ, Gawkrodger D, Collaboration AR. Vitiligo linked to stigmatization in British South Asian women: a qualitative study of the experiences of living with vitiligo. Br J Dermatol. 2010;163:481\u20136.","journal-title":"Br J Dermatol"},{"issue":"10","key":"2875_CR30","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamadermatol.2023.2787","volume":"159","author":"K Bibeau","year":"2023","unstructured":"Bibeau K, Ezzedine K, Harris JE, et al. Mental health and psychosocial quality-of-life burden among patients with vitiligo: findings from the global VALIANT study. JAMA Dermatol. 2023;159(10):1124\u20138.","journal-title":"JAMA Dermatol"},{"key":"2875_CR31","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/j.1365-2133.2008.08881.x","volume":"159","author":"D Gawkrodger","year":"2008","unstructured":"Gawkrodger D, Ormerod A, Shaw L, et al. Guideline for the diagnosis and management of vitiligo. Br J Dermatol. 2008;159:1051\u201376.","journal-title":"Br J Dermatol"},{"key":"2875_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/phpp.12598","volume":"37","author":"JM Bae","year":"2021","unstructured":"Bae JM, Jeong KH, Choi CW, et al. Development of evidence-based consensus on critical issues in the management of patients with vitiligo: a modified Delphi study. Photodermatol Photoimmunol Photomed. 2021;37:3\u201311.","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"2875_CR33","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/jdv.16927","volume":"35","author":"V Narayan","year":"2021","unstructured":"Narayan V, Uitentuis S, Luiten R, Bekkenk M, Wolkerstorfer A. Patients\u2019 perspective on current treatments and demand for novel treatments in vitiligo. J Eur Acad Dermatol Venereol. 2021;35:744\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2875_CR34","doi-asserted-by":"publisher","first-page":"ljad245","DOI":"10.1093\/bjd\/ljad245","volume":"189","author":"IH Hamzavi","year":"2023","unstructured":"Hamzavi IH, Bibeau K, Grimes P, et al. Exploring the natural and treatment history of vitiligo: perceptions of patients and healthcare professionals from the global VALIANT study. Br J Dermatol. 2023;189:ljad245.","journal-title":"Br J Dermatol"},{"key":"2875_CR35","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.jaad.2015.07.039","volume":"73","author":"K Ezzedine","year":"2015","unstructured":"Ezzedine K, Sheth V, Rodrigues M, et al. Vitiligo is not a cosmetic disease. J Am Acad Dermatol. 2015;73:883\u20135.","journal-title":"J Am Acad Dermatol"},{"key":"2875_CR36","doi-asserted-by":"publisher","first-page":"k1786","DOI":"10.1136\/bmj.k1786","volume":"361","author":"RJ Silverwood","year":"2018","unstructured":"Silverwood RJ, Forbes HJ, Abuabara K, et al. Severe and predominantly active atopic eczema in adulthood and long term risk of cardiovascular disease: population based cohort study. BMJ. 2018; 361:k1786. https:\/\/doi.org\/10.1136\/bmj.k1786.","journal-title":"BMJ"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02875-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02875-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02875-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T10:36:01Z","timestamp":1719570961000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02875-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,27]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["2875"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02875-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,27]]},"assertion":[{"value":"23 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y Ramot received speaker honoraria, consultancy fees or travel support from Pfizer, AbbVie, Novartis, Janssen, Sanofi, BI, Neopharm, Dexcel Pharma, Taro, and Lilly. V Rosenberg has nothing to declare. L Zhou and S Harbers are employees of AbbVie and may own AbbVie stock and\/or options.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by the Maccabi Health Services\u2019 Institutional Review Board, reference number MHS-0013-22, who waived the requirement to obtain any informed consent for this secondary analysis of existing data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}